Autoimmune hepatitides--update 2004.

Cell Mol Biol (Noisy-le-grand)

Faculty of Medicine, University of Heidelberg, D-69469 Weinheim, Germany.

Published: July 2005

This update reports is primarily made to update papers published in 2002 and 2003. A selection had to be realized since a search of the literature yielded more than 1600 journal articles. The prevailing opinion of an international group is especially emphasized. Autoimmune hepatitides (AIH)--as the name already suggests it--are no disease entity. We prefer to classify them under the terms of typical and atypical autoimmune hepatitides. Typical autoimmune hepatitis can be subdivided into a type 1 (with antibodies against nuclear material and/or smooth muscle) and a type 2 (with antibodies against endoplasmic reticulum). In the case of atypical autoimmune hepatitides, the detected autoantibodies would have to be stated. The essential feature of an autoimmune hepatitis is the presence of various high-titer autoantibodies circulating in serum, especially such of the IgG class. Special mention is made of the very rare liver ribosomal antibodies (LRA), which are mainly directed against 80S liver ribosomes and point to a so-called virus-associated autoimmune hepatitis. Also discussed are a genetic disposition, which is still speculative in some points, and the existence of so-called autogenes (physiological, pathological/pathogenic and so-called regulator genes). Various noxae, e.g. viruses, might also be "autogenous". Further research in the field of the autoimmune hepatitides (and also autoimmunity and autoimmune diseases as such) is therefore likely to concentrate on viruses and genes and their interrelations.

Download full-text PDF

Source

Publication Analysis

Top Keywords

autoimmune hepatitides
16
autoimmune hepatitis
12
autoimmune
9
atypical autoimmune
8
type antibodies
8
autoimmune hepatitides--update
4
hepatitides--update 2004
4
2004 update
4
update reports
4
reports update
4

Similar Publications

Background: Alanine aminotransferase (ALT) frequently elevates in chronic hepatitis B patients stopping nucleos(t)ide analogs (NAs).

Aims: To clarify the association between ALT elevation and HBsAg seroclearance after NA withdrawal.

Methods: This multicenter cohort study reviewed consecutive patients discontinuing NA between 2004/04/01 and 2022/05/24.

View Article and Find Full Text PDF

Background: Liver function of chronic hepatitis B (CHB) patients is essentially normal after treatment with antiviral drugs. In rare cases, persistently abnormally elevated α-fetoprotein (AFP) is seen in CHB patients following long-term antiviral treatment. However, in the absence of imaging evidence of liver cancer, a reasonable explanation for this phenomenon is still lacking.

View Article and Find Full Text PDF

Extracellular vesicles (EVs) are generated in all cells. Systemic administration of allogenic EVs derived from epithelial and mesenchymal cells has been shown to be safe, despite carrying an array of functional molecules, including thousands of proteins. To address whether epithelial cell-derived EVs can be modified to acquire the capacity to induce an immune response, we engineered 293T EVs to harbor the immunomodulatory molecules CD80, OX40L, and PD-L1.

View Article and Find Full Text PDF

Patients with diabetes are at increased risk of HBV infection; however, the effects of HBV infection and anti-HBV therapy on the management of type 1 diabetes (T1D), type 2 diabetes (T2D), and latent autoimmune diabetes in adults (LADA) remain unclear. From 2016 to 2023, we recruited a multicenter cohort of 355 HBV-infected inpatients, including 136 with T1D, 140 with T2D, and 79 with LADA. The control group included 525 HBV-uninfected inpatients, comparing 171 with T1D, 204 with T2D and 150 with LADA.

View Article and Find Full Text PDF

Update in Clinical Science: Autoimmune Hepatitis.

J Hepatol

January 2025

I. Department of Medicine, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany; European Reference Network on Hepatological Diseases (ERN RARE-LIVER). Electronic address:

Autoimmune hepatitis (AIH) is an enigmatic, relatively rare disease with a variable spectrum of presentation whose pathogenesis, diagnosis and management remain a major challenge. Methods. We have performed a review incorporating recent developments in basic science, epidemiology, clinical science, therapeutics, regulatory science and evaluated the challenges associated with the application of translational research and clinical trial design to a condition that is a chameleon in nature, where outcomes range from relatively benign disease through cirrhosis and acute liver failure.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!